{"changeSha256":"a563391b4a9877fd0e16fb8db4608971a2de9598ca8650df981bd4d21d9f0543","changedAt":"2026-09-15","changedFields":[{"after":"FDA's August 2024 assessment distinguishes ipamorelin free base and acetate and evaluates evidence for growth hormone deficiency and postoperative ileus.","before":"A peptide named in FDA compounding-risk and DOJ enforcement records.","field":"Profile summary"},{"after":"At the time of its assessment, FDA reported that neither form was a component of an FDA-approved drug and found insufficient evidence for the evaluated uses. The advisory briefing is not a final compounding determination.","before":"FDA's compounding-risk page describes immunogenicity and characterization concerns. A separate Justice Department release names Ipamorelin among unapproved new drugs distributed by the cited pharmacy.","field":"Evidence note"},{"after":"fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-ipamorelin-briefing-2024","before":"fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement","field":"Cited source records"},{"after":"name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-ipamorelin-briefing-2024; evidenceNote: fda-ipamorelin-briefing-2024","before":"name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; evidenceNote: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/ipamorelin/versions/2/","version":2},"id":"profile:ipamorelin:v2","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"corrected","notice":"We added FDA's dated assessment to distinguish substance forms, evaluated uses and the advisory stage of review. Earlier profile versions remain available.","peptideSlugs":["ipamorelin"],"previousChangeEvent":null,"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/ipamorelin/versions/1/","version":1},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-ipamorelin-briefing-2024","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA evaluation of ipamorelin-related bulk substances, August 19, 2024","url":"https://www.fda.gov/media/182088/download","verifiedAt":"2026-09-15"}],"subject":{"slug":"ipamorelin","type":"profile"}}